Anthropic Partners with Six Pharma Companies to Accelerate Drug Discovery with Claude

On October 28, Anthropic's life sciences team announced deep research collaborations with six drug development organizations and the launch of its own drug discovery program, marking the AI company's formal move into biomedicine. Partners include BigHat Biosciences, Bristol Myers Squibb, Enveda, Generate Biomedicines, The Column Group, and Divergence. Science team lead ncfrey shared the news on his personal account.

Confirmed

• Anthropic's official blog published the partnership announcement along with research reports. Claude is being used across drug R&D stages including literature synthesis, target research, and trial protocol drafting; the reports also describe both the assistive benefits and limitations.
• The in-house drug discovery program includes the acquisition of one-person company Mithril Medicine. Per the official blog, founder Cody Tranbarger used Claude to organize contracts, logistics, and external collaborations, advancing to the mouse validation stage in roughly 18 months.
• Generate Biomedicines and Anthropic published joint results: six scientists used Claude together with their own models, computational tools, and wet-lab data to reengineer CAR T cell receptors targeting solid tumors. The redesigned signaling components were about 70% shorter than standard designs and showed enhanced cancer-killing capability.

Why it matters

• This is a high-profile AI-for-Science deployment in biomedicine, showing how large models can move from research assistants to being directly embedded in drug development pipelines.
• The Mithril Medicine case is especially striking: a one-person company leveraged Claude to go from logistics to mouse validation within 18 months, offering a concrete example of AI dramatically compressing R&D staffing and timelines.
• The specific experimental result of the CAR T receptor reengineering (70% shorter signaling components) provides a verifiable technical benchmark, and the reports have also sparked discussion in communities like HN.

2026-10-28 ~ 2026-10-28 · 12 related posts

• [source] Anthropic Partners With Six Drug Developers to Speed Medicine Discovery, Launches In-House Programs — AnthropicAI · 2026-10-28
• Generate Biomedicines and Anthropic use Claude to refactor CAR T receptor, cutting signaling component 70% — rbhar90 · 2026-10-28
• [source] Anthropic partners with six drug developers and buys a 1-person biotech — nc_frey · 2026-10-28
• Anthropic Acquires One-Person Drug Company Mithril, Eyes Human Trials by Late 2028 — inductionheads · 2026-10-28
• [source] Anthropic Reports Early Progress Applying Claude to Drug Development — Gab1024 · 2026-10-28
• Anthropic and BigHat Bio Demo Agent-Driven Antibody Engineering with Integrated Wet Lab — anshulkundaje · 2026-10-28
• Anthropic Launches In-House Drug Discovery, with Claude Doing Much of the Scientific Work — ZeroStateReflex · 2026-10-28
• Claude in drug development: 70% shorter CAR-T parts, 89% faster reviews, trials by 2028 — Dr_Singularity · 2026-10-28
• Anthropic shares early results from six Claude drug-discovery partnerships, starts own rare-disease programs — IAmSamFin · 2026-10-28

3 near-duplicate retellings: nlarusstone · mark_k · Dr_Singularity